Abstract: Lonafarnib (SCH66336) is a pioneering small-molecule drug and the first treatment approved by the US Food and Drug Administration (FDA) for Hutchinson-Gilford Progeria Syndrome (HGPS) and processing-deficient progeroid laminopathies. HGPS is a rare, fatal genetic disorder characterized by accelerated aging, primarily driven by the accumulation of a permanently farnesylated, toxic variant of the lamin A protein known as progerin. Lonafarnib functions as a potent, nonpeptidic, CAAX-competitive farnesyltransferase (FTase) inhibitor. By blocking the farnesylation of progerin, it prevents the protein's abnormal accumulation in the inner nuclear membrane, thereby restoring nuclear architecture and improving several clinical manifestations of the disease. Clinical trials have demonstrated that lonafarnib significantly extends the lifespan of HGPS patients and improves cardiovascular, skeletal, and neurological parameters. However, the drug is not a definitive cure and is associated with limitations, including gastrointestinal toxicity, hepatotoxicity, and the potential for alternative prenylation of progerin by geranylgeranyltransferase (GGTase). Consequently, ongoing research is heavily focused on combination therapies, such as co-administration with everolimus, and the exploration of novel downstream targets to further enhance therapeutic efficacy and patient outcomes.
1. Introduction
Hutchinson-Gilford Progeria Syndrome (HGPS), commonly known as progeria, is an extremely rare and fatal autosomal dominant genetic disorder characterized by clinical features that resemble accelerated physiological aging [1][2][3]. The disease affects approximately 1 in 4 to 20 million live births and is caused by a de novo point mutation in exon 11 of the LMNA gene (c.1824C > T; p.G608G) [1][2][3]. This mutation activates a cryptic splice site, leading to the deletion of 50 amino acids and the production of a toxic, truncated version of the lamin A protein called progerin [2][3]. Children with HGPS typically appear normal at birth but soon develop severe symptoms, including growth retardation, loss of subcutaneous fat, lipodystrophy, alopecia, osteoporosis, joint contractures, and progressive atherosclerosis [2][3]. The primary cause of mortality is cardiovascular disease, such as myocardial infarction or stroke, with an average life expectancy of approximately 14.5 years [2][3].
For decades, there was no specific treatment for HGPS. However, in November 2020, lonafarnib (marketed as Zokinvy™) achieved a historic milestone by becoming the first FDA-approved drug to reduce the risk of mortality in HGPS and to treat processing-deficient progeroid laminopathies in patients 12 months of age and older [1][2][4]. Originally discovered by Merck & Co. as an investigational oncology drug, lonafarnib was repurposed for progeria after researchers identified the critical role of protein farnesylation in the disease's pathogenesis [1][2].
2. Pharmacological Activity
The clinical efficacy of lonafarnib in HGPS has been demonstrated through extensive Phase 2 single-arm studies (e.g., NCT00425607 and NCT00916747) comparing treated patients to matched, untreated patients from a natural history cohort [1]. A retrospective survival analysis revealed that lonafarnib monotherapy significantly decreased the mortality rate. Over an 11-year follow-up period, lonafarnib treatment increased the mean lifespan of HGPS patients by an average of 2.5 years (mean survival time of 8.0 years in treated patients versus 5.5 years in untreated patients) [1].
Beyond extending lifespan, lonafarnib improves several phenotypic hallmarks of progeria. Clinical assessments showed that treatment for two or more years increased the annual rate of weight gain in a subset of patients [1]. Cardiovascular and skeletal benefits were also observed, including a median 35% decrease in arterial pulse wave velocity (indicating reduced vascular stiffness), decreased carotid artery echodensity, and increased skeletal rigidity [1]. Neurologically, lonafarnib treatment reduced the prevalence of strokes and transient ischemic attacks, and significantly decreased the frequency of headaches [1].
Pharmacokinetically, lonafarnib is administered orally. In HGPS patients, the median time to peak plasma concentration (tmax) at steady state is 2 to 4 hours [1]. The drug is highly protein-bound (≥ 99%) and is primarily metabolized by the CYP3A enzyme family [1]. Its absorption is influenced by food intake; administration with a high-fat meal decreases the peak plasma concentration (Cmax) and area under the curve (AUC) by 55% and 29%, respectively, compared to fasted conditions [1].
3. Molecular Mechanism of Action
The therapeutic rationale for lonafarnib in HGPS is deeply rooted in the post-translational processing of the lamin A protein. Normal prelamin A undergoes a sequence of modifications at its C-terminal CAAX motif: farnesylation of the cysteine residue by farnesyltransferase (FTase), cleavage of the terminal tripeptide, carboxymethylation, and a final cleavage by the metallopeptidase ZMPSTE24 to remove the farnesylated tail [1][2]. In HGPS, the 50-amino-acid deletion in progerin eliminates the ZMPSTE24 recognition site. Consequently, progerin cannot undergo the final cleavage step and remains permanently farnesylated and carboxymethylated [1][2][5].
This permanent lipid anchor causes progerin to accumulate abnormally in the inner nuclear membrane, disrupting the nuclear lamina, causing misshapen (blebbed) nuclei, and triggering downstream cellular defects such as chromatin disorganization, DNA damage, and premature senescence [1][2]. Lonafarnib acts as a potent, selective FTase inhibitor (FTI). By inhibiting FTase, lonafarnib prevents the attachment of the 15-carbon farnesyl lipid group to progerin [1][2]. In vitro studies have shown that blocking this farnesylation restores normal nuclear architecture and significantly reduces nuclear blebbing in human HGPS fibroblasts, thereby mitigating the cellular toxicity associated with the disease [1].
4. Structure-Activity Relationship (SAR)
Chemically, lonafarnib is designated as 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5Hbenzo[1,2] cyclohepta [2,4-b]pyridin-11-yl]piperidin-1-yl]-2- oxoethyl] piperidine-1-carboxamide [1]. It belongs to a class of non-peptidomimetic, small-molecule FTase inhibitors containing halogenated hydrocarbons, piperidines, and pyridines [1][5].
Lonafarnib functions as a CAAX-competitive inhibitor [1]. The FTase enzyme normally recognizes the CAAX tetrapeptide motif (where C is cysteine, A is an aliphatic amino acid, and X is any amino acid) at the C-terminus of target proteins like prelamin A and Ras [2][5]. Lonafarnib competes with this motif for the binding site on the FTase enzyme. By occupying the active site, the drug effectively blocks the enzyme from transferring the farnesyl pyrophosphate lipid to the cysteine residue of the target protein [1][5]. Its non-peptidic structure provides it with the necessary stability and oral bioavailability that earlier peptide-based inhibitors lacked, allowing it to be successfully translated into clinical use [1][4].
5. Current Limitations
Despite its landmark approval, lonafarnib is a disease-modifying treatment rather than a definitive cure, and it presents several clinical and mechanistic limitations. First, while it improves certain symptoms and extends lifespan, it does not fully correct all disease manifestations, such as lipodystrophy, alopecia, and joint contractures [2]. Furthermore, cardiovascular complications remain the leading cause of morbidity and mortality in treated patients, indicating that defective angiogenesis and atherosclerosis are not entirely halted by FTase inhibition [3].
Mechanistically, the efficacy of lonafarnib is limited by alternative prenylation pathways. When FTase is inhibited, progerin (like Ras proteins) can undergo alternative prenylation by the enzyme geranylgeranyltransferase (GGTase) [2][5]. This compensatory mechanism allows a portion of progerin to still anchor to the nuclear membrane, blunting the therapeutic impact of the drug [2].
Additionally, lonafarnib is associated with a significant adverse event profile. The most frequent side effects are gastrointestinal, including vomiting (90%), diarrhea (81%), and nausea (56%), which can lead to treatment discontinuation [1][4]. Other common issues include decreased appetite, fatigue, and infections [1]. Severe risks include hepatotoxicity, with elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) observed in 27% to 35% of patients, as well as hypertension [1][4]. Furthermore, because lonafarnib was originally developed as an antiproliferative oncology drug, long-term treatment in progeroid cells (which require pro-proliferative signals) has been linked to cellular toxicity and the formation of abnormal "donut-shaped" nuclei [2].
6. Future Perspectives
To address the limitations of lonafarnib monotherapy, current research is heavily focused on combination regimens and novel therapeutic targets. To counteract alternative prenylation by GGTase, clinical trials previously explored a triple therapy combining lonafarnib with the statin pravastatin and the bisphosphonate zoledronic acid (which inhibit upstream steps in the mevalonate pathway) [1][2]. However, this combination did not yield significant advantages over lonafarnib alone and was discontinued [1][2].
Currently, a Phase 1/2 dose-escalation study (NCT02579044) is investigating the combination of lonafarnib with everolimus, an mTOR inhibitor [1][2]. Everolimus induces autophagy, which may help clear the toxic accumulation of progerin from cells, potentially offering a synergistic effect when combined with FTase inhibition [2].
Beyond FTase inhibitors, the pipeline for HGPS therapeutics is expanding. New small molecules are being developed, such as isoprenylcysteine carboxylmethyltransferase (ICMT) inhibitors (e.g., UCM-13207) and inhibitors that directly block the interaction between progerin and lamin A (e.g., progerinin, currently in Phase 1 trials) [2]. Furthermore, advanced biological therapies, including antisense oligonucleotides (ASOs) and CRISPR/Cas9-based in vivo base editing, hold immense promise for directly correcting the underlying LMNA genetic mutation, paving the way toward a definitive cure for HGPS in the future [2].
